Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

This study has been completed.
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland Identifier:
First received: July 18, 2006
Last updated: June 11, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2012
  Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)